WL Gore and Associates granted CE Mark for vascular graft

WL Gore and Associates has received approval to launch its new Gore Propaten Vascular Graft for haemodialysis access in Europe.

The medical device has been granted CE Mark accreditation for use in this new application, allowing it to be utilised to address the blood treatment needs of kidney failure patients.

Among the beneficial features of the device are its covalent bonding technology and expanded polytetrafluoroethylene construction, which improve its efficacy, handling properties and ease of use.

It has been approved in Europe for lower extremity applications for more than a decade and has built up several years' worth of positive clinical data supporting its effectiveness.

Erin Hutchinson, associate for Gore's peripheral vascular business unit, said: "Gore is committed to providing new technologies for the treatment of end-stage renal disease and the potential therapeutic benefits for dialysis access patients."

Last month, the company released its new Viabahn Endoprosthesis stent-graft device in Europe, having received CE Mark approval late last year.